#big pharma jobs
How Big Pharma got the better of Ottawa Add to.
Dr. John Bergeron pulls his car off Highway 40 in west Montreal and turns into a desolate parking lot beside a sprawling complex of buildings. Walking across the parking lot, he greets two men. One of them is Dr. Ronald Guttmann, who, like Bergeron, is a retired McGill professor who has spent many years working on the discovery, development and commercialization of new drugs. The third man is Dr. Samir Mounir, a scientific entrepreneur and former team leader at BioChem Pharma, which at one time was Canada’s biggest homegrown medical-sciences company.
To continue reading this article, you must be a Globe Unlimited subscriber.
Don’t stop here. Go unlimited.
A Globe Unlimited subscription also gives you:
- Full access to all our award-winning news articles and exclusive features
- Access and availability on all devices and platforms
- Real-time Stock Quotes that remove the 15-minute stock price delay on all Canadian stock portals
- Reuters Financial News providing key insights from the world’s best economies and markets newsroom
Subscribe to Globe Unlimited now!
Already a Globe Unlimited subscriber? Log in to keep reading.
BNN’s Catherine Murray speaks wtih Corey Davis, a Specialty Pharmaceuticals analyst with Canaccord Genuity, about the most recent sell-off in biotech stocks and how Hillary Clinton’s new plan to deal with costs of prescription drugs is affecting market sentiment. BNN Video
Michael Pearson, chief executive officer of Valeant Pharmaceuticals International Inc. waits for the start of their annual general meeting in Laval, Que. in 2014. Reuters
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc. waits for the start of their annual general meeting in Laval, Quebec May 20, 2014. REUTERS
Thomson Reuters 2012.
All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.
Selected data supplied by Thomson Reuters. Thomson Reuters Limited. Click for Restrictions .
Copyright 2016 The Globe and Mail Inc. All Rights Reserved.
444 Front St. W. Toronto. ON Canada M5V 2S9
Phillip Crawley, Publisher